MacroGenics, Inc. announced on March 20, 2025, its financial results for the fourth quarter and full year ended December 31, 2024. The company reported a loss for the fourth quarter and lagged revenue estimates.
A significant corporate update included the decision to discontinue further internal clinical development of vobramitamab duocarmazine (vobra duo). MacroGenics is now exploring potential partnering alternatives for this B7-H3 targeting program.
As of December 31, 2024, MacroGenics held $201.7 million in cash, cash equivalents, and marketable securities. This balance is projected to support the company's cash runway into the second half of 2026, funding planned investments in ongoing clinical and preclinical programs.
Despite the discontinuation of vobra duo, MacroGenics confirmed the full enrollment of its LORIKEET Phase 2 study for lorigerlimab in combination with docetaxel for mCRPC patients. The company is also initiating a new LINNET Phase 2 study for lorigerlimab in ovarian cancer and advancing other novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028, and MGC030.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.